These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 21566519)

  • 21. Differential diagnosis of benign and malignant mesothelial proliferations on pleural biopsies.
    Cagle PT; Churg A
    Arch Pathol Lab Med; 2005 Nov; 129(11):1421-7. PubMed ID: 16253023
    [TBL] [Abstract][Full Text] [Related]  

  • 22. p53 immunostaining in the distinction between benign and malignant mesothelial proliferations using formalin-fixed paraffin sections.
    Mayall FG; Goddard H; Gibbs AR
    J Pathol; 1992 Dec; 168(4):377-81. PubMed ID: 1484319
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Insulin-like growth factor II messenger RNA-binding protein 3 expression in gastrointestinal mesenchymal tumors.
    Yamamoto H; Arakaki K; Morimatsu K; Zaitsu Y; Fujita A; Kohashi K; Hirahashi M; Motoshita J; Oshiro Y; Oda Y
    Hum Pathol; 2014 Mar; 45(3):481-7. PubMed ID: 24411949
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transforming growth factor alpha and epidermal growth factor receptor in reactive and malignant mesothelial proliferations.
    Cai YC; Roggli V; Mark E; Cagle PT; Fraire AE
    Arch Pathol Lab Med; 2004 Jan; 128(1):68-70. PubMed ID: 14692808
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 5-hmC loss is another useful tool in addition to BAP1 and MTAP immunostains to distinguish diffuse malignant peritoneal mesothelioma from reactive mesothelial hyperplasia in peritoneal cytology cell-blocks and biopsies.
    Alsugair Z; Kepenekian V; Fenouil T; Glehen O; Villeneuve L; Isaac S; Hommell-Fontaine J; Benzerdjeb N
    Virchows Arch; 2022 Jul; 481(1):23-29. PubMed ID: 35575935
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of cell cycle state may facilitate the histopathological diagnosis of malignant mesothelioma.
    Sington JD; Morris LS; Nicholson AG; Coleman N
    Histopathology; 2003 May; 42(5):498-502. PubMed ID: 12713628
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Highlights of the 14th international mesothelioma interest group meeting: Pathologic separation of benign from malignant mesothelial proliferations and histologic/molecular analysis of malignant mesothelioma subtypes.
    Churg A; Nabeshima K; Ali G; Bruno R; Fernandez-Cuesta L; Galateau-Salle F
    Lung Cancer; 2018 Oct; 124():95-101. PubMed ID: 30268487
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The separation of benign and malignant mesothelial proliferations.
    Churg A; Colby TV; Cagle P; Corson J; Gibbs AR; Gilks B; Grimes M; Hammar S; Roggli V; Travis WD
    Am J Surg Pathol; 2000 Sep; 24(9):1183-200. PubMed ID: 10976692
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Myogenic antigen expression is useful for differentiation between epithelioid mesothelioma and non-neoplastic mesothelial cells.
    Tsukiji H; Takeshima Y; Amatya VJ; Kushitani K; Inai K
    Histopathology; 2010 Jun; 56(7):969-74. PubMed ID: 20636799
    [No Abstract]   [Full Text] [Related]  

  • 30. Benign and malignant mesothelial proliferations.
    Koss LG
    Am J Surg Pathol; 2001 Apr; 25(4):548-9. PubMed ID: 11257637
    [No Abstract]   [Full Text] [Related]  

  • 31. 9p21 deletion in the diagnosis of malignant mesothelioma, using fluorescence in situ hybridization analysis.
    Takeda M; Kasai T; Enomoto Y; Takano M; Morita K; Kadota E; Nonomura A
    Pathol Int; 2010 May; 60(5):395-9. PubMed ID: 20518890
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas.
    Chiosea S; Krasinskas A; Cagle PT; Mitchell KA; Zander DS; Dacic S
    Mod Pathol; 2008 Jun; 21(6):742-7. PubMed ID: 18327208
    [TBL] [Abstract][Full Text] [Related]  

  • 33. My approach to the diagnosis of mesothelial lesions.
    Butnor KJ
    J Clin Pathol; 2006 Jun; 59(6):564-74. PubMed ID: 16731600
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative immunohistochemical analysis of IMP3, GLUT1, EMA, CD146, and desmin for distinguishing malignant mesothelioma from reactive mesothelial cells.
    Minato H; Kurose N; Fukushima M; Nojima T; Usuda K; Sagawa M; Sakuma T; Ooi A; Matsumoto I; Oda M; Arano Y; Shimizu J
    Am J Clin Pathol; 2014 Jan; 141(1):85-93. PubMed ID: 24343741
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Primary thymic epithelial tumours of the pleura mimicking malignant mesothelioma.
    Attanoos RL; Galateau-Salle F; Gibbs AR; Muller S; Ghandour F; Dojcinov SD
    Histopathology; 2002 Jul; 41(1):42-9. PubMed ID: 12121236
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The differential diagnosis of epithelial-type mesothelioma from adenocarcinoma and reactive mesothelial proliferation.
    Soosay GN; Griffiths M; Papadaki L; Happerfield L; Bobrow L
    J Pathol; 1991 Apr; 163(4):299-305. PubMed ID: 2033489
    [TBL] [Abstract][Full Text] [Related]  

  • 37. c-MET immunohistochemistry for differentiating malignant mesothelioma from benign mesothelial proliferations.
    Ren HZ; Cheung S; Churg A
    Hum Pathol; 2020 Nov; 105():31-36. PubMed ID: 32916162
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group.
    Husain AN; Colby TV; Ordóñez NG; Krausz T; Borczuk A; Cagle PT; Chirieac LR; Churg A; Galateau-Salle F; Gibbs AR; Gown AM; Hammar SP; Litzky LA; Roggli VL; Travis WD; Wick MR
    Arch Pathol Lab Med; 2009 Aug; 133(8):1317-31. PubMed ID: 19653732
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is D2-40 a useful marker for distinguishing malignant mesothelioma from pulmonary adenocarcinoma and benign mesothelial proliferations?
    Deniz H; Kibar Y; Güldür ME; Bakir K
    Pathol Res Pract; 2009; 205(11):749-52. PubMed ID: 19573998
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Utility of glucose transporter 1 in the distinction of benign and malignant thoracic and abdominal mesothelial lesions.
    Lagana SM; Taub RN; Borczuk AC
    Arch Pathol Lab Med; 2012 Jul; 136(7):804-9. PubMed ID: 22742553
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.